A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
- Summary
- Ovarian cancer (OC) is a lethal disease. The purpose of this study is to assess the safety, pharmacokinetics and efficacy of ABBV901, alone or in combination with bevacizumab, in participants with ovarian cancer. ABBV901 is an investigational drug for the treatment of ovarian cancer. This study has 4 Parts (Arms) where participants will receive ABBV-901, alone or in combination with the standard available therapy, bevacizumab. Around 219 participants will be enrolled in the study at approximately 75 sites around the world. In part 1, participants will receive escalating doses of intravenous (IV) ABBV-901 alone. In part 2, participants will receive 1 of 3 doses of IV ABBV-901, alone to determine the optimized dose. In part 3, participants will receive escalating doses of IV ABBV-901, combination with IV bevacizumab. In part 4, participants will receive recommended doses for expansion of IV ABBV-901, combination with IV bevacizumab. The total study duration will be approximately 3 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.
- Short title
- A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
- Official title
- A Phase 1 First-in-Human, Open-Label Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-901 as a Monotherapy and in Combination With Bevacizumab in Adult Subjects With Ovarian Cancer
- Control arm
- Open label
- Registry reports results
- Listing at source
- Listed
- Recruitment status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Completion date
- 2029-01-01
- First posted
- 2025-12-12
- Registry last updated
- 2026-07-15
- Primary completion date
- 2029-01-01
- Start date
- 2025-11-27
- Participants
- Participant count basis
- Estimated
- Planned participants
- Protocol amendments
- Number of sites
- Data monitoring committee
- Registry sponsor category
- Industry
- Lead sponsor
- AbbVie
- Source registry
- ClinicalTrials.gov
- Registry ID
- NCT07278336
- ClinicalTrials.gov ID
- NCT07278336
- Registry record
- Open registry record
- Allocation
- Randomised
- Model
- Sequential
- Purpose
- Treatment
- Masking
- No masking
Number of Participants with Adverse Events (AE)
Timeframe: Up to Approximately 3 Years
An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have a causal relationship with this treatment.
Overall Response
Timeframe: Up to Approximately 3 Years
Overall response is defined as participants achieving confirmed complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as assessed by the investigator.
Duration of Response (DOR)
Timeframe: Up to Approximately 3 Years
DOR is defined for participants achieving a confirmed PR or better as the time from the initial response of PR (or better) per investigator review according to RECIST Version 1.1 criteria to disease progression or death of any cause, whichever occurs earlier.
Progression-free survival (PFS)
Timeframe: Up to Approximately 3 Years
PFS is defined as time from first study treatment to a documented disease progression according to RECIST Version 1.1 (or other assessment criteria), as determined by the investigator, or death due to any cause, whichever occurs earlier.
Overall Survival (OS)
Timeframe: Up to Approximately 3 Years
OS is defined as time from first study treatment to death due to any cause.
Disease Control Rate
Timeframe: Up to Approximately 3 Years
Disease Control Rate is defined as the percentage of participants with best overall response (BOR) of stable disease (SD), PR or better per investigator review according to RECIST version 1.1 criteria.
- Sex
- All
- Age groups
- Adults, Older adults
- Minimum age
- 18 Years
- Healthy volunteers
- No
-
Diagnosis of an advanced or unresectable malignant high grade serous epithelial ovarian, fallopian tube, and primary peritoneal cancers (EOC), fallopian tube or primary peritoneal cancer by histology (World Health Organization [WHO] criteria).
-
Participants must be considered platinum resistant or platinum ineligible. Platinum resistant disease is defined as radiographic progression within 6 months (up to 182 days) after the last dose of the most recent platinum therapy).
-
Prior anticancer therapy:
- Must have received appropriate standard of care therapy and be appropriate for participation in a Phase I study in the opinion of the investigator.
- Platinum-resistant, high grade serous EOC cannot have had more than 2 prior lines of therapy, since the development of platinum resistance or ineligibility.
-
For participants enrolled in backfill, subjects must provide consent to paired biopsies which are pretreatment and on-treatment tumor biopsies from the same tumor lesion.
- Ovarian Cancer (OC) with histologies other than high grade serous OC including endometrioid, low grade, clear cell, mucinous, or borderline ovarian tumor.
- Prior therapy with an antibody-drug conjugate containing a topoisomerase inhibitor.
- Prior history of Grade >= 2 ILD or pneumonitis.
- History of interstitial lung disease (ILD) or pneumonitis that required treatment with systemic steroids, or any evidence of active ILD or pneumonitis on Screening chest computed tomography (CT) scan.
- Must not have systemically used known strong cytochrome P450 (CYP)3A inhibitors or inducers within 14 days or 5 half-lives of the drug (whichever is shorter) prior to the first dose of the study drug through the end of the DLT observation period. If clinically indicated, strong CYP3A inhibitors and inducers may be used with caution after the dose-limiting toxicity (DLT) period.
- Sarah Cannon Research Institute at HealthONE /ID# 278785Denver, United StatesRecruiting
- University of Chicago Medical Center /ID# 278295Chicago, United StatesRecruiting
- NEXT Oncology - San Antonio /ID# 278606San Antonio, United StatesRecruiting
- Start Mountain Region /ID# 278609West Valley City, United StatesRecruiting
- Next Virginia /ID# 278607Fairfax, United StatesRecruiting
- Sun Yat-Sen University Cancer Center /ID# 282505Guangzhou, ChinaNot yet recruiting
- Qilu Hospital Of Shandong University /ID# 283564Jinan, ChinaNot yet recruiting
- Shandong Cancer Hospital /ID# 283566Jinan, ChinaNot yet recruiting
- Fudan University Shanghai Cancer Center /ID# 282600Shanghai, ChinaNot yet recruiting
- The Chaim Sheba Medical Center /ID# 278416Ramat Gan, IsraelRecruiting
- Rambam Health Care Campus /ID# 278418Haifa, IsraelRecruiting
- Hadassah Medical Center-Hebrew University /ID# 278420Jerusalem, IsraelRecruiting
- National Cancer Center Hospital East /ID# 278604Kashiwa-shi, JapanRecruiting
- Saitama Medical University International Medical Center /ID# 278437Hidaka, JapanRecruiting
- Shizuoka Cancer Center /ID# 278538Sunto-gun, JapanRecruiting
- New Zealand Clinical Research (Christchurch) /ID# 281467Christchurch, New ZealandNot yet recruiting
- Taipei Veterans General Hospital /ID# 281349Taipei, TaiwanRecruiting
- 2025
- 2025-522209-40-00
Related records
Drugs (1)
Lead sponsors (1)
Conditions (2)
- Ovarian cancer Primary condition
- Ovarian neoplasm